Journal
EPILEPSIA
Volume 51, Issue 10, Pages 1970-1977Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1528-1167.2010.02670.x
Keywords
Complex partial seizures; Epilepsy; Generalized tonic-clonic seizures; Phenytoin; Rapid-initiation; Topiramate
Categories
Funding
- Ortho-McNeil Janssen Scientific Affairs, LLC.
- Abbott Laboratories
- Bertex
- Carter-Wallace
- Cephalon
- Cyberonics
- Eisai
- GlaxoSmithKline
- IVAX
- Marion Merrell Dow
- Novartis
- Ortho-McNeil Pharmaceuticals
- Ovation Pharmaceuticals
- Pfizer
- RW Johnson
- Schwarz Pharma
- SmithKline Beecham
- UCB Pharma
- X-cel Pharma
- Ortho-McNeil/JohnsonJohnson
- Schwarz Pharma/UCB
- American Epilepsy Society
- EpiFellows Foundation
- Janssen-Cilag
- National Institutes of Health
- Pfizer Inc
Ask authors/readers for more resources
P>Purpose: To evaluate topiramate (TPM) and phenytoin (PHT) monotherapy following rapid oral initiation in new-onset epilepsy. Methods: Randomized, double-blind, 28-day trial of TPM (100 mg/day beginning on day 1) versus PHT (1,000 mg on day 1 followed by 300 mg/day maintenance dosing) in 261 patients with new-onset epilepsy. The primary end point was time to seizure, and the primary objective was to establish noninferiority of TPM to PHT in the risk of seizure. Results: At day 28, the estimated seizure-free rate was 81.1% for TPM treatment in comparison with 90.3% for PHT treatment. Noninferiority of TPM to PHT (primary objective) could not be established [hazard ratio (HR) 2.0, 95% confidence interval (CI), 0.98 to 4.12, p = 0.366), and PHT could not be shown to be superior to TPM. A higher percentage discontinued with PHT compared to TPM for all reasons (21.1 vs. 12.8%) and due to adverse events (13.4 vs. 6.8%). The most common treatment-related adverse events in both groups were dizziness, paresthesia, and somnolence. A post hoc analysis showed that TPM was superior to PHT in time to discontinuation (retention rate) for all causes (89.4% vs. 80.3%, p = 0.047). Conclusion: This study was inconclusive in establishing noninferiority of TPM 100 mg/day compared to a standard regimen of oral PHT in seizure risk in this population of patients with new-onset epilepsy. Given the superiority of TPM in overall retention and favorable tolerability without titration, it may nonetheless be an appropriate option in some patients with new-onset epilepsy requiring rapid treatment initiation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available